Special Issue

Antiprotozoal Activity of Natural Products

Message from the Guest Editors

Neglected tropical diseases (NTDs), caused by protozoan parasites, are the leading cause of morbidity and mortality among the world's low-income populations. Of the 17 major NTDs, the life-threatening diseases Leishmaniasis, Malaria, Chagas disease, and human African Trypanosomiasis (HAT) are considered the most challenging due to their limited therapeutic options and high mortality rates. The absence of eagerly desired vaccines and the availability of limited chemotherapeutics, some with reduced efficacy and considerable drawbacks, hinder the efficient treatment of these diseases. Therefore, the discovery and development of novel effective, safe, and inexpensive antiprotozoal agents remain an urgent need. In this scenario, natural products can play an important role as potential lead compounds as they might have advantages over conventional chemical-based drugs. On this basis, this Special Issue is designed to gather review papers and original articles dealing with the potential antiprotozoal activities of plant secondary metabolites, including different classes such as terpenoids, alkaloids and phenolics.

Guest Editors

Prof. Dr. Filippo Maggi
School of Pharmacy, University of Camerino, 62032 Camerino, Italy

Dr. Riccardo Petrelli
Chemistry Interdisciplinary Project (CHIP), School of Pharmacy, University of Camerino, Via Madonna delle Carceri, 62032 Camerino, Italy

Deadline for manuscript submissions

closed (15 February 2023)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/67546

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI